Dr. Kristina Deligiannidis is the Director of Women’s Behavioral Health at Zucker Hillside Hospital, Northwell Health and a Professor of Psychiatry, Molecular Medicine and Obstetrics and Gynecology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. As Director, she leads a clinical/translational research program and advises on policies and services promoting women’s behavioral health at Northwell Health.

Dr. Deligiannidis additionally serves as the Medical Director for Reproductive Psychiatry for the perinatal psychiatry access program, Project TEACH, funded by the Office of Mental Health. There Dr. Deligiannidis leads a maternal mental health team to provide education and phone consultation to maternal health clinicians on perinatal mental health disorders across the state. As a reproductive psychiatrist, she has expertise in treating women with mood and anxiety disorders linked to the menstrual cycle, perinatal and perimenopausal periods.

Dr. Deligiannidis is a nationally recognized leader in the field of perinatal depression and in novel therapeutics research. Her research program includes a focus in psychoneuroendocrinology, particularly neurosteroids and hormones, and multimodal neuroimaging in women’s behavioral health. Dr. Deligiannidis’s research is supported by NIH R01, foundation and industry funding. Her efforts have been nationally recognized with many awards for research and medical student and resident teaching. She has published numerous peer-reviewed manuscripts and has given over 200 oral presentations/research posters at local, national and international scientific conferences. Her recent publications have been in high impact journals including the Lancet, Lancet Psychiatry, JAMA Psychiatry, American Journal of Psychiatry, Neuropsychopharmacology and Molecular Psychiatry. Her research has been covered by major media outlets (>100 interviews in the past few years), including CNN, the Associated Press, NPR All Things Considered, NPR 1A, the Boston Globe, CBS Sunday Morning, the Canadian Broadcasting Company, the Wall Street Journal, Time Magazine, Good Morning America and others.

Dr. Deligiannidis actively contributes to national scientific committees and gives scientific presentations nationally and internationally. She is a current Board of Directors member for the Marcé of North America, past Council member of the Society of Biological Psychiatry, past Board of Directors member for the American Society of Clinical Psychopharmacology and currently is a full member of the American College of Neuropsychopharmacology where she serves on the Gender Equity and Inclusion Committee. Dr. Deligiannidis also serves as a reviewer on over 20 scientific journals and on Editorial Boards of national and international journals. She serves as a federal grant reviewer for the Center for Scientific Review at NIH.

Dr. Deligiannidis received her medical degree from and completed her psychiatry residency and chief residency in psychopharmacology research at the University of Massachusetts Medical School. Prior to and during medical school she trained in neuroscience research at the National Institutes of Health. After residency she completed additional research training in behavioral endocrinology and experimental therapeutics at the NIH and in neuroimaging at the Martinos Center for Biomedical Imaging at Massachusetts General Hospital.